Updated
Atopic dermatitis: Asian pipelines and global competitors
As of 2026-11-14, Asian participation in atopic dermatitis includes Simcere’s rademikibart, Chugai-originated nemolizumab and SinoMab’s SM17, targeting IL-4Rα, IL-31RA and the IL-25 receptor pathway, respectively. Approved global comparators include dupilumab and lebrikizumab. Kyowa Kirin announced discontinuation of all ongoing rocatinlimab trials on 2026-03-03; it is listed separately as a discontinued program.
Selected systemic biologics; oral JAK inhibitors and topical medicines are not exhaustively covered. Originator and regional rights are distinguished.
Asian companies
| Asset | Company | Mechanism / route | Stage | Indication | Trial ID | Deal / rights | Latest verified record | Sources |
|---|---|---|---|---|---|---|---|---|
rademikibart | Simcere / Connect | Anti-IL-4Rα antibody SC | Phase 3 completed; NDA withdrawn with resubmission planned | Moderate-to-severe atopic dermatitis | — | Simcere holds China development, manufacturing and commercialization rights; amounts not verified | The 04-22 release says the NDA was withdrawn, with resubmission planned that month; primary confirmation of reacceptance was not identified. | |
nemolizumab / NEMLUVIO | Chugai; Galderma and regional partners | Anti-IL-31RA antibody SC | Approved; indications vary by jurisdiction | Atopic dermatitis / associated pruritus, per local labels | — | No verified deal terms identified | Chugai announced a drug-discovery award for nemolizumab; this is a research award, not a new indication approval. | |
SM17 | SinoMab (Hong Kong) | Anti-IL-25 receptor (IL17RB) antibody SC | Phase 2; recruiting per registry | Moderate-to-severe atopic dermatitis | No verified deal terms identified | Reported first dosing in China Phase 2 on 03-31; approximately 210 participants are planned, not confirmed enrolled. |
Global comparators
| Asset | Company | Mechanism / route | Stage | Indication | Latest verified record | Sources |
|---|---|---|---|---|---|---|
dupilumab / Dupixent | Sanofi / Regeneron | Anti-IL-4Rα antibody SC | Approved | Atopic dermatitis; ages depend on jurisdiction | Signed a Canadian pCPA letter of intent including pediatric AD; this does not establish reimbursement in every province. | |
lebrikizumab / EBGLYSS | Eli Lilly | Anti-IL-13 antibody SC | Approved | Moderate-to-severe atopic dermatitis | Q3 results highlighted Phase 3 hand-and-foot AD data; this is not a new approval announcement. |
Discontinued program
| Asset | Company | Mechanism / route | Stage | Indication | Latest verified record | Sources |
|---|---|---|---|---|---|---|
rocatinlimab | Kyowa Kirin | Anti-OX40 antibody SC | Discontinued; historical Phase 3 program | Moderate-to-severe AD and other indications | Announced discontinuation of all ongoing trials following emerging safety concerns. |
Events in the last 90 days
2026-08-17 – 2026-11-14
lebrikizumab / EBGLYSS
Q3 results highlighted Phase 3 hand-and-foot AD data; this is not a new approval announcement. Primary source
dupilumab / Dupixent
Signed a Canadian pCPA letter of intent including pediatric AD; this does not establish reimbursement in every province. Primary source
nemolizumab / NEMLUVIO
Chugai announced a drug-discovery award for nemolizumab; this is a research award, not a new indication approval. Primary source
Sources and downloads
- Simcere HKEX regulatory update — 2026-04-22
- Simcere RADIANT-AD — 2026-03-30
- Chugai nemolizumab award — 2026-09-07
- SinoMab HKEX first patient dosed — 2026-04-01
- SM17 Phase 2 registry — 2026-04-06
- Sanofi Canada pCPA LOI — 2026-10-15
- Lilly Q3 2026 results — 2026-10-29
- Kyowa Kirin discontinuation — 2026-03-03
Information cutoff 2026-11-14